Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Sees Significant Decrease in Short Interest

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 2 shares, a decrease of 98.5% from the June 15th total of 137 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 2,784 shares, the short-interest ratio is currently 0.0 days.

Enzon Pharmaceuticals Stock Performance

ENZN remained flat at $4.40 during trading on Friday. The company had a trading volume of 4,182 shares, compared to its average volume of 970. The company has a 50-day moving average of $5.55 and a 200-day moving average of $5.68. The firm has a market capitalization of $3.26 million, a P/E ratio of -0.64 and a beta of -0.05. Enzon Pharmaceuticals has a 1 year low of $1.50 and a 1 year high of $11.10. The company has a current ratio of 2.01, a quick ratio of 1.16 and a debt-to-equity ratio of 0.42.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last announced its earnings results on Monday, May 4th. The biotechnology company reported ($0.84) EPS for the quarter. The business had revenue of $86.54 million for the quarter.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.